Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Beta and Glucocorticoids in New-onset ANCA-Associated Glomerulonephritis
NCT07746180Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab beta in ANCA-associated glomerulonephritis (ANCA-GN), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Chinese PLA General Hospital. Started Aug 2026; status: recruiting.
02
Drugs
obinutuzumab beta
03
Conditions
ANCA-associated glomerulonephritis (ANCA-GN)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07746180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746180.